Dr. Nagendra Verma | Life Sciences | Best Researcher Award

Research specialist| St. Cloud State University | United States

Dr. Nagendra Verma is a highly accomplished biomedical scientist specializing in cellular and molecular biology, molecular oncology, and regenerative medicine, with over a decade of international research experience. His work focuses on the therapeutic and regulatory roles of extracellular vesicles (EVs) and microRNAs in ocular and cancer biology, particularly exploring their applications in corneal wound healing, stem cell regulation, and STAT3-dependent cancer inhibition. Dr. Verma has authored 11 research publications, cited 104 times by 95 documents, achieving an h-index of 7. His research demonstrates a strong command of molecular diagnostics, genomics, and biophysical methodologies, contributing to significant advancements in understanding disease mechanisms and developing novel therapeutic interventions. He has collaborated extensively within interdisciplinary academic and industrial environments, reflecting his ability to integrate scientific innovation with translational potential. As an active member of global scientific societies such as ARVO, RAPS, and AAMI, Dr. Verma also serves as a reviewer and editorial board member for numerous international journals, including Scientific Reports, Cells, and Molecular Vision. His contributions extend beyond research through mentoring students, presenting at international conferences, and earning recognition for excellence in scientific investigation. Dr. Verma’s work continues to bridge molecular insights with therapeutic innovation, emphasizing precision, collaboration, and impactful discovery in biomedical science.

Profiles: Scopus | Orcid

Featured Publications

Verma, N., Franchitto, M., Zonfrilli, A., Cialfi, S., Palermo, R., & Talora, C. (2019). DNA damage stress: Cui prodest? International Journal of Molecular Sciences, 20(5), 1073.
Verma, N., Khare, D., Poe, A. J., Amador, C., Ghiam, S., Fealy, A., Ebrahimi, S., Shadrokh, O., Song, X.-Y., Santiskulvong, C., et al. (2023). MicroRNA and protein cargos of human limbal epithelial cell-derived exosomes and their regulatory roles in limbal stromal cells of diabetic and non-diabetic corneas. Cells, 12.
Verma, N., Arora, S., Singh, A. K., & Kumar, A. (2025). Extracellular vesicle-associated miRNAs in cornea health and disease: Diagnostic potential and therapeutic implications. Targets, 3(32).
Verma, N., Arora, S., Singh, A. K., & Ahmed, J. (2025). Unlocking the potential of exosomes (extracellular vesicles): Drug delivery advancements and therapeutics in ocular diseases. RSC Pharmaceutics, 1(97).
Verma, N., & Arora, S. (2025). Navigating the global regulatory landscape for exosome-based therapeutics: Challenges, strategies, and future directions. Pharmaceutics, 17(990).
Arora, S., & Verma, N. (2024). Advancing organic electronics through the lens of ionic liquids and polymerized ionic liquids: A review. RSC Applied Polymers.
Arora, S., & Verma, N. (2024). Exosomal microRNAs as potential biomarkers and therapeutic targets in corneal diseases. Molecular Vision, 30, 92–106.
De Blasio, C., Verma, N., Moretti, M., Cialfi, S., Zonfrilli, A., Franchitto, M., Truglio, F., De Smaele, E., Ichijo, H., Naguro, I., Screpanti, I., & Talora, C. (2021). Functional cooperation between ASK1 and p21(Waf1/Cip1) in the balance of cell-cycle arrest, cell death, and tumorigenesis of stressed keratinocytes. Cell Death Discovery, 7(1), 75.
De Blasio, C., Zonfrilli, A., Franchitto, M., Mariano, G., Cialfi, S., Verma, N., Checquolo, S., Bellavia, D., Palermo, R., Benelli, D., Screpanti, I., & Talora, C. (2019). PLK1 targets NOTCH1 during DNA damage and mitotic progression. Journal of Biological Chemistry, 294(47), 17941–17950.
Yue, P., Zhu, Y., Brotherton-Pleiss, C., Fu, W., Verma, N., Chen, J., Nakamura, K., Chen, W., Chen, Y., Alonso-Valenteen, F., Mikhael, S., Medina-Kauwe, L., Kershaw, K. M., Celeridad, M., Pan, S., Limpert, A. S., Sheffler, D. J., Cosford, N. D. P., Shiao, S. L., & Turkson, J. (2022). Novel potent azetidine-based compounds irreversibly inhibit STAT3 activation and induce antitumor response against human breast tumor growth in vivo. Cancer Letters, 534, 215613.

Dr. Jorge Perea Armijo| Medicina | Best Researcher Award

Cardiology,Reina Sofia University Hospital,Spain

Dr. Jorge Perea Armijo has demonstrated a sustained and focused research trajectory in the field of cardiovascular medicine, with a clear emphasis on heart failure, complex coronary interventions, and electrophysiology. His authorship in numerous peer-reviewed articles between 2023 and 2025 — many of which are multi-center, collaborative, and published in high-impact journals — reflects both his scientific rigor and collaborative acumen. His contributions indicate a strong alignment with clinical translational research, likely impacting patient care directly.

Profile:

Scopus

ORCID Profile

Education

Dr. Jorge Perea Armijo holds a medical degree and specialized training in internal medicine, with further subspecialization in infectious diseases. He completed his undergraduate medical studies at a leading Spanish university and pursued residency training in internal medicine at a tertiary care center. His academic journey continued with a fellowship in infectious diseases, focusing on complex infections in immunocompromised patients.

Professional Experience

Currently, Dr. Perea Armijo serves as a physician at the Hospital Universitario Reina Sofía, where he is involved in both clinical care and academic medicine. Over the years, he has accumulated extensive experience in hospital-based medicine, with a focus on the diagnosis and management of infectious diseases, including antimicrobial stewardship and infection prevention practices. He has also contributed to the training of medical residents and students.

Skills

Dr. Perea Armijo is highly skilled in clinical decision-making, infectious disease diagnostics, and patient safety initiatives. He is proficient in the use of electronic health record systems, and he regularly collaborates with interdisciplinary teams to optimize patient outcomes. His ability to communicate complex medical concepts effectively has made him a valuable educator and mentor.

Research Interests

His research is centered on the clinical management of multidrug-resistant organisms, the impact of infections in transplant recipients, and the development of hospital-based infection control protocols. He is an advocate for evidence-based approaches to infectious disease treatment and has participated in multiple multicenter studies examining new antimicrobial therapies

Honors and Awards

Throughout his career, Dr. Perea Armijo has received several awards recognizing his excellence in clinical care and medical education. These include commendations from his hospital for patient-centered care initiatives and grants supporting his infectious disease research

Publication :

Heredia-Campos, G., Rodríguez-Gómez, M.E., Perea-Armijo, J., González-Manzanares, R., Castillo-Domínguez, J.C., Delgado-Ortega, M., Crespin-Crespin, M., Ruiz-Ortiz, M., Mesa-Rubio, D., Ladera-Santos, D., et al. (2025). Insuficiencia cardiaca con fracción de eyección reducida: influencia del género en las características clínicas, el remodelado cardiaco y la respuesta neurohormonal. Medicina Clínica.
Gallo, I., Azzalini, L., González-Manzanares, R., Moscardelli, S., Jurado-Román, A., Maestre, L.C., Suárez de Lezo, J., Hidalgo, F., Perea, J., Díaz, M., et al. (2025). Mechanical Circulatory Support With Impella in High‐Risk Patients With Chronic Total Occlusion and Complex Multivessel Disease. Catheterization and Cardiovascular Interventions.
Perea-Armijo, J., Gutiérrez-Ballesteros, G., Mazuelos-Bellido, F., González-Manzanares, R., Huelva, J.M., López-Aguilera, J., Pan, M., Segura Saint-Gerons, J.M. (2025). Comparison of left bundle branch area pacing between patients with pacing-induced cardiomyopathy and non-ischemic dilated cardiomyopathy. Current Problems in Cardiology.
Hidalgo, F., González-Manzanares, R., Suárez de Lezo, J., Gallo, I., Alvarado, M., Perea, J., Maestre-Luque, L.C., Resúa, A., Romero, M., López-Benito, M., et al. (2024). The Usefulness of Coregistration with iFR in Tandem or Long Diffuse Coronary Lesions: The iLARDI Randomized Clinical Trial. Journal of Clinical Medicine.
Maestre-Luque, L.C., González-Manzanares, R., Suárez de Lezo, J., Hidalgo, F., Barreiro-Mesa, L., de Juan, J., Gallo, I., Perea, J., Alvarado, M., Romero, M., et al. (2024). Complete vs. incomplete percutaneous revascularization in patients with chronic total coronary artery occlusion. Frontiers in Cardiovascular Medicine.
Pan, M., Pericet, C., González-Manzanares, R., Díaz, M.A., Suárez de Lezo, J., Hidalgo, F., Alvarado, M., Dueñas, G., Gómez, E., Espejo, S., Perea, J., et al. (2024). Very long-term follow-up after aortic stenting for coarctation of the aorta. Revista Española de Cardiología (English Edition).
Perea Armijo, J., Pan Álvarez-Ossorio, M., Romero Moreno, M. (2023). Closure of nontraumatic complex arteriovenous fistula. Revista Española de Cardiología.
Gallo Fernández, I., Rodríguez Nieto, J., Perea Armijo, J., Pastor Wulf, D., López Baizán, J., Delgado Ortega, M. (2023). Middle-aged woman with congestive symptoms: more than just pulmonary arterial hypertension. Revista Española de Cardiología.
Perea, J., López-Aguilera, J., González-Manzanares, R., Pericet-Rodríguez, C., Castillo-Domínguez, J.C., Heredia-Campos, G., Roldán-Guerra, Á., Urbano-Sánchez, C., Barreiro-Mesa, L., Aguayo-Caño, N., et al. (2023). The Worsening of Heart Failure with Reduced Ejection Fraction: The Impact of the Number of Hospital Admissions in a Cohort of Patients. Journal of Clinical Medicine.
Perea-Armijo, J., López-Aguilera, J., Sánchez-Prats, R., Castillo-Domínguez, J.C., González-Manzanares, R., Ruiz-Ortiz, M., Mesa-Rubio, D., Anguita-Sánchez, M. (2023). Improvement of left ventricular ejection fraction in patients with heart failure with reduced ejection fraction: Predictors and clinical impact. Medicina Clínica.

conclusion:

Dr. Jorge Perea Armijo is a highly qualified and impactful clinical researcher in cardiology. He possesses a robust track record of peer-reviewed research that is both clinically relevant and scientifically sound. His breadth across subfields of cardiovascular medicine, along with his consistent productivity, make him a strong candidate for a Best Researcher Award, particularly within hospital-based or national cardiology networ